NEWS
25/06/2024
Kanin Wichapong presents a state-of-the-art lecture during the World Congress of the International Society on Thrombosis and Haemostasis in Bankok, Thailand, titled: "Structural Bioinformatics technologies for rational drug design: from in silico to in vivo"
15/05/2024
Kanin Wichapong gives an oral presentation during the 2nd ML4NGP MEETING on Machine Learning and Non-globular protein in Thessaloniki, Greece titled: "Development of machine learning algorithms for the prediction of the binding affinity between peptides and their target proteins"
15/05/2025
Gerry Nicolaes was invited to pitch and present Hillmark at the Brightlands AI Pitch Event, that was held during the ICT & Health World Conference in Maastricht, the Netherlands
10/04/2024
A poster was presented at the congress of the European Federation for Medicinal Chemistry in Utrecht the Netherlands, titled:
"Structure-based discovery and optimization of a TRAF2 small molecule inhibitor", show casing a succesfull project for the discovery and optimization of an orally available small molecule inhibitor with in vivo activity.
14/09/2023
A poster was presented at the European Congress on Thrombosis and Haemostasis in Valencia, Spain titled:
"Application of Computer-Based Methods to Discover and Optimize Bioactive Compounds with Anti-Inflammatory and Anti-Atherosclerotic Activities: from In Silico to In Vivo"
representing several showcases of Hillmark technologies
25/05/2023
An interview about our start-up is published in the “Glossy Magazine - 10 Years Brightlands Maastricht Health Campus” and is also available online.
Meet & Greet 2022 at Bandito Espresso
15/03/2023
Researchers from Hillmark (Dr. Gerry Nicolaes and Dr. Kanin Wichapong) have received research funding from the European Commission - the 2022 Marie Skłodowska-Curie Actions (MSCA) call for Doctoral Networks. The research funding will allow both researchers together with international collaborators to establish a consortium (PRAETORIAN: EuroPean Training NetwoRks to TArget DAMPs and NETs: novel apprOaches in pRecision SepsIs pAtieNt care) to investigate molecular mechanism of DAMPs and NETs inducing sepsis which will lead to development of novel theranostic (therapeutic and diagnostic) for sepsis. The project will last for 4 years (2024-2028).